Efficacy of Scalp Cooling Combined with DHL-HisZnNa Lotion in the Prevention of Chemotherapy-Induced Alopecia in Patients with Breast Cancer

This study explored the effectiveness of combining scalp cooling therapy with a DHL-HisZnNa-containing lotion to prevent chemotherapy-induced alopecia (CIA) in breast cancer patients. Among 23 analyzed participants, 91.3% showed improvement in hair loss 90 days post-chemotherapy, with all patients improving to Grade 1 alopecia or lower. The combination therapy was effective in preventing severe hair loss and demonstrated favorable safety, though some patients still experienced Grade 1 alopecia. The study noted that specific chemotherapy regimens, like the TC regimen, might delay hair volume recovery. Despite the small sample size and absence of a control group, the findings suggest this approach could enhance quality of life by reducing CIA and promoting hair regrowth, though further research is needed.